Apex, NC, United States of America

Kathryn K Taylor

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Bayer Corporation, Talecris Biotherapeutics, Inc.. Active years: 2002-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kathryn K Taylor. Retrieved from https://idiyas.com/inventor/kathryn-k-taylor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 2002-2005

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Revolutionizing Thrombolysis: The Innovations of Kathryn K. Taylor

Introduction

Kathryn K. Taylor is an accomplished inventor based in Apex, NC, who has made significant contributions to the field of thrombolytic therapy through her groundbreaking patents. With a total of two registered patents, her inventions focus on improving methods for treating vascular thrombotic occlusions, showcasing her dedication to advancing medical technology and patient care.

Latest Patents

Kathryn's latest patents include two remarkable methods of thrombolysis. The first patent, titled "Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin," introduces methods that combine a fibrinolytic composition containing reversibly inactivated acidified plasmin with localized delivery techniques. This innovation aims to minimize systemic degradation of fibrin while maximizing the plasmin's activity against thrombus, ultimately enhancing the effectiveness of thrombolysis treatments.

The second patent, "Method of thrombolysis by local delivery of active plasmin," presents an advanced approach to thrombolytic therapy by facilitating direct administration of active plasmin to a clot site via catheter. This process not only includes an active stable preparation of plasmin but also outlines effective methods for its activation and isolation, which could lead to more successful treatment outcomes for patients suffering from vascular occlusions.

Career Highlights

Over the years, Kathryn has been associated with prominent companies, including Bayer Corporation and Talecris Biotherapeutics, Inc., where she has worked on innovative solutions in medical science. Her experiences at these organizations have contributed significantly to her expertise and advancements in thrombolytic therapy.

Collaborations

During her career, Kathryn has collaborated with esteemed professionals like Valery Novokhatny and Gary J. Jesmok. These partnerships have fostered an environment of creativity and discovery, allowing her to develop and refine her innovative concepts.

Conclusion

Kathryn K. Taylor's contributions to the field of thrombolytic therapy stand as a testament to her ingenuity and dedication. Her patented methods demonstrate a significant potential for improving patient outcomes in the treatment of vascular thrombotic occlusions. With her continued passion for innovation, Kathryn is sure to inspire future advancements in medical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…